2-methylthio-5-(1-methyl-2-imidazolylhydroxymethyl)-6-(3-chloro-4-methoxybenzylamino)-pyrimidine | 454486-92-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-methylthio-5-(1-methyl-2-imidazolylhydroxymethyl)-6-(3-chloro-4-methoxybenzylamino)-pyrimidine
• 英文别名: 4-(3-chloro-4-methoxybenzylamino)-5-[(hydroxy) (1-methyl-2-imidazolyl)methyl]-2-methylthiopyrimidine；[4-(3-Chloro-4-methoxy-benzylamino)-2-methylsulfanyl-pyrimidin-5-yl]-(1-methyl-1H-imidazol-2-yl)-methanol；4-(3-Chloro-4-methoxybenzylamino)-5-[(hydroxy)(1-methyl-2-imidazolyl)methyl]-2-methylthiopyrimidine；[4-[(3-chloro-4-methoxyphenyl)methylamino]-2-methylsulfanylpyrimidin-5-yl]-(1-methylimidazol-2-yl)methanol
• CAS: 454486-92-1
• 化学式: C₁₈H₂₀ClN₅O₂S
• 分子量: 405.908
• InChiKey: IDPSUDXVEGQVCQ-UHFFFAOYSA-N

物化性质

• 沸点：
  662.7±55.0 °C(Predicted)
• 密度：
  1.39±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  110
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2-methylthio-5-(1-methyl-2-imidazolylhydroxymethyl)-6-(3-chloro-4-methoxybenzylamino)-pyrimidine 在 二氧化锰 作用下， 以 氯仿 为溶剂， 反应 72.0h， 生成 [4-(3-Chloro-4-methoxy-benzylamino)-2-methylsulfanyl-pyrimidin-5-yl]-(1-methyl-1H-imidazol-2-yl)-methanone
  参考文献：
  名称：

  EP1364950

  摘要：

  公开号：
• 作为产物：
  描述：

  N-甲基咪唑 、 4-(3-Chloro-4-methoxy-benzylamino)-2-methylsulfanyl-pyrimidine-5-carbaldehyde 在 正丁基锂 、 碳酸氢钠 作用下， 以 四氢呋喃 、 正己烷 、 水 为溶剂， 反应 2.5h， 生成 2-methylthio-5-(1-methyl-2-imidazolylhydroxymethyl)-6-(3-chloro-4-methoxybenzylamino)-pyrimidine
  参考文献：
  名称：

  EP1364950

  摘要：

  公开号：

文献信息

• Cyclic compounds
  申请人：——

  公开号：US20040142930A1

  公开（公告）日：2004-07-22

  1. A cyclic compound of the formula (I) or a pharmacologically acceptable salt thereof, 1 wherein X is ═CH— or ═N—, Y is —NH—, —NR 4 —, —S—, —O—, —CH═N—, —N═CH—, —N═N—, —CH═CH—, etc., R 1 is a lower alkoxy group, an amino group, a heterocyclic ring containing N atom(s), or a hydroxy group substituted by a heterocyclic ring containing N atom(s) (each of which is optionally substituted), R 2 is a lower alkylamino group which is optionally substituted by an aryl group, a lower alkoxy group which is optionally substituted by an aryl group, a lower alkoxy group substituted by an aromatic heterocyclic ring containing N atom(s), R 3 is an aryl group, a heterocyclic ring containing N atom(s), a lower alkyl group, a lower alkoxy group, a cyclo lower alkoxy group, a hydroxy group substituted by a heterocyclic ring containing N atom(s), or an amino group (each of which is optionally substituted), and R 3 and a substituent in Y may be combined to form a lactone ring. The compound of the present invention has excellent selective PDE V inhibitory activity and therefore, is useful as a therapeutic or prophylactic drug for treating various diseases due to functional disorders on cGMP-signaling.

  化合物的公式（I）或其药理学上可接受的盐，其中X为═CH—或═N—，Y为—NH—，—NR4—，—S—，—O—，—CH═N—，—N═CH—，—N═N—，—CH═CH—等，R1为较低的烷氧基，氨基，含N原子的杂环环，或者由含N原子的杂环环取代的羟基（每个都可以取代），R2为较低的烷基氨基基，可以由芳基取代，较低的烷氧基，可以由芳基取代，由含N原子的芳基取代的较低的烷氧基，R3为芳基，含N原子的杂环环，较低的烷基，较低的烷氧基，环状较低的烷氧基，由含N原子的杂环环取代的羟基，或者氨基（每个都可以取代），R3和Y中的取代基可以结合形成内酯环。本发明的化合物具有优异的选择性PDE V抑制活性，因此，可用作治疗或预防因cGMP信号传导功能障碍引起的各种疾病的药物。
• Pyrazine derivatives
  申请人：Tanabe Seiyaku Co., Ltd.

  公开号：US07273868B2

  公开（公告）日：2007-09-25

  1. A cyclic compound of the formula (I) or a pharmacologically acceptable salt thereof, wherein X is ═CH— or ═N—, Y is —NH—, —NR4—, —S—, —O—, —CH═N—, —N═CH—, —N═N—, —CH═CH—, etc., R1 is a lower alkoxy group, an amino group, a heterocyclic ring containing N atom(s), or a hydroxy group substituted by a heterocyclic ring containing N atom(s) (each of which is optionally substituted), R2 is a lower alkylamino group which is optionally substituted by an aryl group, a lower alkoxy group which is optionally substituted by an aryl group, a lower alkoxy group substituted by an aromatic heterocyclic ring containing N atom(s), R3 is an aryl group, a heterocyclic ring containing N atom(s), a lower alkyl group, a lower alkoxy group, a cyclo lower alkoxy group, a hydroxy group substituted by a heterocyclic ring containing N atom(s), or an amino group (each of which is optionally substituted), and R3 and a substituent in Y may be combined to form a lactone ring. The compound of the present invention has excellent selective PDE V inhibitory activity and therefore, is useful as a therapeutic or prophylactic drug for treating various diseases due to functional disorders on cGMP-signaling.

  公式（I）的环状化合物或其药学上可接受的盐，其中X为═CH—或═N—，Y为—NH—、—NR4—、—S—、—O—、—CH═N—、—N═CH—、—N═N—、—CH═CH—等，R1为较低的烷氧基、氨基、含N原子的杂环环或由含N原子的杂环环取代的羟基（每个都可以选择性地取代），R2为较低的烷基氨基，可以选择性地被芳基取代，也可以选择性地被芳基取代的较低的烷氧基，被含N原子的芳香杂环环取代的较低的烷氧基，R3为芳基、含N原子的杂环环、较低的烷基、较低的烷氧基、环状较低的烷氧基、由含N原子的杂环环取代的羟基或氨基（每个都可以选择性地取代），R3和Y中的取代基可以结合形成内酯环。本发明的化合物具有出色的选择性PDE V抑制活性，因此，可用作治疗或预防因cGMP信号传导功能障碍引起的各种疾病的药物。
• Pyrimidine compounds
  申请人：Tanabe Seiyaku Co., Ltd.

  公开号：US07220736B2

  公开（公告）日：2007-05-22

  A cyclic compound of the formula (I) or a pharmacologically acceptable salt thereof, wherein X is ═CH— or ═N—, Y is —NH—, —NR4—, —S—, —O—, —CH═N—, —N═CH—, —N═N—, —CH═CH—, etc., R1 is a lower alkoxy group, an amino group, a heterocyclic ring containing N atom(s), or a hydroxy group substituted by a heterocyclic ring containing N atom(s) (each of which is optionally substituted), R2 is a lower alkylamino group which is optionally substituted by an aryl group, a lower alkoxy group which is optionally substituted by an aryl group, a lower alkoxy group substituted by an aromatic heterocyclic ring containing N atom(s), R3 is an aryl group, a heterocyclic ring containing N atom(s), a lower alkyl group, a lower alkoxy group, a cyclo lower alkoxy group, a hydroxy group substituted by a heterocyclic ring containing N atom(s), or an amino group (each of which is optionally substituted), and R3 and a substituent in Y may be combined to form a lactone ring. The compound of the present invention has excellent selective PDE V inhibitory activity and therefore, is useful as a therapeutic or prophylactic drug for treating various diseases due to functional disorders on cGMP-signaling.

  公式（I）的环状化合物或其药理学上可接受的盐，其中X为═CH—或═N—，Y为—NH—、—NR4—、—S—、—O—、—CH═N—、—N═CH—、—N═N—、—CH═CH—等，R1为较低的烷氧基、氨基、含有N原子的杂环环或被含有N原子的杂环环取代的羟基（每个都可以选择性地取代），R2为较低的烷基氨基基，其可选择性地被芳基基团取代，较低的烷氧基，其可选择性地被芳基基团取代，被含有N原子的芳杂环取代的较低的烷氧基，R3为芳基、含有N原子的杂环环、较低的烷基、较低的烷氧基、环状较低烷氧基、被含有N原子的杂环环取代的羟基或氨基（每个都可以选择性地取代），并且R3和Y中的取代基可以结合形成内酯环。本发明化合物具有优异的选择性PDE V抑制活性，因此，可用作治疗或预防因cGMP信号传导功能障碍引起的各种疾病的药物。
• CYCLIC COMPOUNDS
  申请人：TANABE SEIYAKU CO., LTD.

  公开号：EP1277741A1

  公开（公告）日：2003-01-22

  1. A cyclic compound of the formula (I) or a pharmacologically acceptable salt thereof,    wherein X is =CH-or=N-, Y is-NH-, -NR4-, -S-, - O-, -CH=N-, -N=CH-, -N=N-, -CH=CH-, etc., R1 is a lower alkoxy group, an amino group, a heterocyclic ring containing N atom(s), or a hydroxy group substituted by a heterocyclic ring containing N atom(s) (each of which is optionally substituted), R2 is a lower alkylamino group which is optionally substituted by an aryl group, a lower alkoxy group which is optionally substituted by an aryl group, a lower alkoxy group substituted by an aromatic heterocyclic ring containing N atom(s), R3 is an aryl group, a heterocyclic ring containing N atom(s), a lower alkyl group, a lower alkoxy group, a cyclo lower alkoxy group, a hydroxy group substituted by a heterocyclic ring containing N atom(s), or an amino group (each of which is optionally substituted), and R3 and a substituent in Y may be combined to form a lactone ring.    The compound of the present invention has excellent selective PDE V inhibitory activity and therefore, is useful as a therapeutic or prophylactic drug for treating various diseases due to functional disorders on cGMP-signaling.

  1.式（I）的环状化合物或其药理学上可接受的盐、 其中 X 是 =CH-or=N-, Y 是-NH-、-NR4-、-S-、-O-、-CH=N-、-N=CH-、-N=N-、-CH=CH-等、R1 是低级烷氧基、氨基、含 N 原子的杂环或被含 N 原子的杂环取代的羟基（其中每一个都可选择被取代）， R2 是低级烷基氨基，可选择被芳基取代，低级烷氧基，可选择被芳基取代、R3 是芳基、含 N 原子的杂环、低级烷基、低级烷氧基、环低级烷氧基、被含 N 原子的杂环取代的羟基或氨基（其中每个基团都可选择被取代），R3 和 Y 中的一个取代基可结合形成一个内酯环。 本发明的化合物具有优异的选择性 PDE V 抑制活性，因此可用作治疗或预防药物，用于治疗因 cGMP 信号转导功能紊乱而引起的各种疾病。
• PYRIDOPYRIMIDINE OR NAPHTHYRIDINE DERIVATIVE
  申请人：TANABE SEIYAKU CO., LTD.

  公开号：EP1364950A1

  公开（公告）日：2003-11-26

  A pyridopyrimidine or a naphthyridine derivative of the formula (I): wherein R1 is an optionally substituted nitrogen-containing heterocyclic group, etc.; R2 is H or a lower alkyl group; R3 is H or an optionally substituted lower alkyl group, etc.; R4 is H, a lower alkyl group, COOH, etc.; R5 is H, an optionally substituted aryl, etc; one of X and Y is CH and the other is nitrogen, or both of X and Y are nitrogen; or a pharmaceutically acceptable salt thereof, these compounds exhibiting excellent PDE V inhibitory activities, and being useful in the prophylaxis or treatment of penile erectile dysfunction, etc.

  式（I）的吡啶嘧啶或萘啶衍生物： 其中 R1 是任选取代的含氮杂环基团等； R2 是 H 或低级烷基； R3 是 H 或任选取代的低级烷基等； R4 是 H、低级烷基、COOH 等； R5 是 H、任选取代的芳基等； X 和 Y 中的一个是 CH，另一个是氮。这些化合物具有优异的 PDE V 抑制活性，可用于预防或治疗阴茎勃起功能障碍等。